🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT05122936
Enrolling by invitation Observational

Observation on Obesity Undergoing XOWI

NCT05122936 · tracked via the Priya Life Science China tracker
Sponsor
Feng Tao
Phase
Observational
Started
2021-11-30
Last updated
2024-03-22

Condition(s) studied

ObesityTraditional Chinese Medicine

Investigational drug(s) / intervention(s)

XRXPY-based Obesity Wellness Intervention(SOWI)

XRXPY-based Obesity Wellness Intervention(SOWI): It is an integrated obesity wellness intervention, composing of lifestyle invention and Chinese herbal therapy (XRXP granule, twice daily, oral administration). XRXPY is made in accordance with standard procedures. Participants will be instructed by TCM practitioner and educated by nutritionist. They will perform diet self-report by WeChat, recording daytime physical active steps and all-day sleeping time by electric bracelet. All the participants will be followed every 2-4 weeks by means of out-patient clinic, phone call or WeChat.

Study summary

Obesity becomes a worldwide chronic health problem, including China. Meta-analyses showed in recent years anti-obesity effects of Chinese herbal therapy (CHT) in overweight and obese patients. However, there are still few observational studies on its effect in patients undergoing CHT more than 6 months, or on its safety. This is a mono-centric, prospective study conducted at Shanghai Municipal Hospital of Traditional Chinese Medicine. Patients with body mass index ≥ 28 Kg/m2 and chartered by heat-dampness is consecutively recruited. All the patients will undergo an integrated SRXPY-based Obesity Wellness Intervention (lifestyle invention + XRXP granule). Patients will be instructed by Traditional Chinese Medicine(TCM) practitioner and nutritionist. They will be investigated every 3 months, until 2 years after enrollment. The study will test anti-obesity effect and safety of the integrated obesity wellness intervention, and test changes of appetite, health-related quality of life, bio markers as well.

Eligibility

Sex
ALL
Min age
18 Years
Max age
70 Years
Healthy volunteers
No
Inclusion Criteria: ·age ranged from 16-70 years old body mas index over 28kg/m2 Exclusion Criteria: * secondary cause of obesity such as hypothalamic obesity, cushing syndrome, and hypophysis dysfunction, etc. * pregnancy or lactation * significant dysfunction of heart, liver, kidney and systemic organs (NYHA Class III or IV; alanine aminotransferase(ALT) and / or aspartate aminotransferase(AST) ≥ 5 times the normal upper limit; glomerular filtration rate\< 60(ml/min) or with malignant tumor * body weight fluctuated by more than 5 kg in the last 3 months with drug abuse or alcohol addiction * with serious mental and neurological disorders * blood pressure ≥ 180/110 mmHg, or malignant hypertension * organic and systemic diseases intolerant of herb

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Shanghai Municipal Hospital of Traditional Chinese Medicine Shanghai Shanghai Municipality

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05122936 on ClinicalTrials.gov ↗ ← All trials in China